A few days after Novartis announced Kymriah’s list price in Germany – i.e. 320’000 € – the G-BA has started the procedure to review the CAR-T for treating forms of child (ALL) and adult (DLBCL) leukemias. The G-BA review, that will be finalized in mid-December 2018,  will feed into price negotiations between Novartis and the German health insurances that will take place in 2019.

Previous PostNext Post